Eleonora Di Paolo

Eleonora Di Paolo

Auto-generated profile, based on publicly available information

Eleonora Di Paolo

Department of BioSciences and Centre for Stem Cell Research, Università degli Studi di Milano, 20122 Milan, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2014 in Cell Death & Differentiation
Verified
Journal Article
Closed access
MVM Valenza
M Valenza
MMM Marullo
M Marullo
EPE Di Paolo
E Di Paolo
ECE Cesana
E Cesana
CZC Zuccato
C Zuccato
ECElena Cattaneo
Elena Cattaneo

20 November 2015 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
MVMarta Valenza
Marta Valenza
JCJane Y Chen
Jane Y Chen
EPEleonora Di Paolo
Eleonora Di Paolo
BRBarbara Ruozi
Barbara Ruozi
DBDaniela Belletti
Daniela Belletti
ECElena Cattaneo
Elena Cattaneo
Brain cholesterol biosynthesis and cholesterol levels are reduced in mouse models of Huntington9s disease (HD), suggesting that locally synthesized, newly formed cholesterol is less available to neurons. This may be detrimental for neuronal function, especially given that locally synthesized cholesterol is implicated in synapse integrity and remodeling. Here, we used biodegradable and biocompatible polymeric nanoparticles (NPs) modified with glycopeptides (g7) and loaded with cholesterol (g7‐NPs‐Chol), which per se is not blood–brain barrier (BBB) permeable, to obtain high‐rate cholesterol delivery into the brain after intraperitoneal injection in HD mice. We report that g7‐NPs, in contrast to unmodified NPs, efficiently crossed the BBB and localized in glial and neuronal cells in different brain regions. We also found that repeated systemic delivery of g7‐NPs‐Chol rescued synaptic and cognitive dysfunction and partially improved global activity in HD mice. These results demonstrate that cholesterol supplementation to the HD brain reverses functional alterations associated with HD and highlight the potential of this new drug‐administration route to the diseased brain. Synopsis Cholesterol in brain is largely derived by local synthesis. One affected pathway in Huntington9s disease (HD) implicates that reduced production and/or availability of brain cholesterol may be detrimental for neuronal function. Polymeric nanoparticles (NPs) loaded with cholesterol, modified with glycopeptides g7 (g7‐NPs‐Chol) to cross the BBB after systemic injection, have been used to deliver cholesterol to the brain of HD mice. These NPs, applied for the first time to a brain disorder, are made of PLGA, which is approved by FDA in various drug delivery systems in humans. Systemic administration of g7‐NPs‐Chol (i) rescued synaptic communication in striatal medium‐sized spiny neurons, (ii) prevented cognitive decline, and (iii) restored the levels of proteins that compose the synaptic machinery in HD mice. g7‐NPs or cholesterol itself did not induce inflammatory response in the periphery, where almost all g7‐NPs are localized.

1 February 2017 in Neurobiology of Disease
Verified
Journal Article
Closed access
MSMahalakshmi Shankaran
Mahalakshmi Shankaran
EPEleonora Di Paolo
Eleonora Di Paolo
VLValerio Leoni
Valerio Leoni
CCclaudio caccia
claudio caccia
CBCostanza Ferrari Bardile
Costanza Ferrari Bardile
MVMarta Valenza
Marta Valenza

21 January 2015 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
CLClotilde Lauro
Clotilde Lauro
MCMyriam Catalano
Myriam Catalano
EPEleonora Di Paolo
Eleonora Di Paolo
GCGiuseppina Chece
Giuseppina Chece
ICIda de Costanzo
Ida de Costanzo
CLCristina Limatola
Cristina Limatola
Neuronal death induced by overactivation of N-methyl-d-aspartate receptors (NMDARs) is implicated in the pathophysiology of many neurodegenerative diseases such as stroke, epilepsy and traumatic brain injury. This toxic effect is mainly mediated by NR2B-containing extrasynaptic NMDARs, while NR2A-containing synaptic NMDARs contribute to cell survival, suggesting the possibility of therapeutic approaches targeting specific receptor subunits. We report that fractalkine/CX3CL1 protects hippocampal neurons from NMDA-induced cell death with a mechanism requiring the adenosine receptors type 2A (A2AR). This is different from CX3CL1-induced protection from glutamate-induced cell death, that fully depends on A1R and requires in part A3R. We show that CX3CL1 neuroprotection against NMDA excitotoxicity involves D-serine, a co-agonist of NR2A/NMDAR, resulting in cyclic AMP-dependent transcription factor (CREB) phosphorylation.

13 September 2016 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
EPEleonora Di Paolo
Eleonora Di Paolo
MVMarta Valenza
Marta Valenza
JCJane Y Chen
Jane Y Chen
BRBarbara Ruozi
Barbara Ruozi
DBDaniela Belletti
Daniela Belletti
ECElena Cattaneo
Elena Cattaneo
Background Several studies provide evidence that brain cholesterol biosynthesis is reduced in several rodent models of Huntington’s disease1,2,3 and a similar reduction is also measurable in HD patients, even before disease onset.4,5 This dysfunction may be detrimental for neuronal cells, especially given that locally synthesised cholesterol is implicated in neurite outgrowth, synapses formation and maintenance, synaptic activity and integrity, and optimal neurotransmitter release.6 Aims We tested the hypothesis that exogenous cholesterol supplementation in the brain of HD mice, by applying different delivery strategies, could rescue aspects of neuronal dysfunction. Methods and results In our first study, the delivery of cholesterol via brain-permeable polymeric nanoparticles (g7-NPs-Chol) rescued synaptic communication, protected from cognitive decline and partially improved global activity in HD mice (Valenza et al., 2015). In a second ongoing study, cognitive functions are significantly improved in HD mice intrastriatally infused with cholesterol, at a continuous rate, via osmotic minipumps, compared to vehicle-treated and untreated HD mice. More recently, we have also adopted a third innovative strategy based on intranasal delivery of cholesterol and the relative preliminary results will be presented. Conclusions Our results highlight the positive effect of cholesterol supplementation to reverse the cascade of synaptic and neuronal alterations associated with the disease. To establish the therapeutic regimen for cholesterol administration will advance significantly towards the concept of cholesterol as a candidate drug in HD. References Valenza et al. J Neurosci 2005 Oct 26;25(43):9,932–7 Valenza et al. Hum Mol Genet 2007 Sep 15;16(18):2,187–98 Valenza et al. J Neurosci 2010 Aug 11;30(32):10,844–50 Leoni et al. Brain 2008 Nov;131(Pt 11):2,851–9 Leoni et al. Neurobiol Dis 2013 Jul;55:37–43 Pfrieger et al. Biochim Biophys Acta 2003 Mar 10;1610(2):271–80